Arnold & Porter Advises Mayne Pharma Group on $430 Million Deal
Arnold & Porter recently advised Mayne Pharma Group Limited, an Australian Securities Exchange-listed specialty pharmaceutical company focused commercialization, on its entry into a scheme implementation deed with Cosette Pharmaceuticals, Inc., a U.S.-based fully integrated pharmaceutical company with a portfolio of products in women's health and dermatology. Cosette is backed by Avista Capital Partners, a healthcare-focused private equity firm, with funds managed by Hamilton Lane, a private markets investment management firm.
In the transaction, Cosette will acquire all of Mayne's outstanding shares at AUD$7.40 per share, for a total consideration of approximately US$430 million.
The deal is expected to close in the second quarter of 2025.
The Arnold & Porter team included partners Derek Stoldt, Tracy Belton, and Debbie Feinstein, senior counsel Sheryl Gittlitz, counsel Peter Danias, and associates Greg Criscitello, Adrian Chochorek, and Nasro Abbas. Gilbert + Tobin served as co-legal advisors for Mayne.
